Free Trial
→ Reagan’s former tech advisor sharing bombshell announcement (From Banyan Hill Publishing) (Ad)tc pixel

ImmuPharma (LON:IMM) Trading 13.9% Higher - Time to Buy?

Written by MarketBeat
September 12, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock price surged by 13.9% to GBX 12.67 ($0.17), showing a significant increase in trading volume by 548% compared to its average session.
  • The company reported a net margin of 3,519.56% but has a negative return on equity of 131.41%, with an expectation of posting substantially negative earnings per share for the current fiscal year.
  • ImmuPharma is a biopharmaceutical company focused on peptide-based therapeutics, including its lead program Lupuzor™ aimed at treating autoimmune diseases like Lupus.
  • MarketBeat previews top five stocks to own in October.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 13.9% during mid-day trading on Wednesday . The company traded as high as GBX 15.15 ($0.21) and last traded at GBX 12.67 ($0.17). 50,412,297 shares changed hands during mid-day trading, an increase of 548% from the average session volume of 7,783,485 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Price Performance

The firm has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The firm has a 50-day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.93.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.